On the afternoon of August 9, Utkirjon Muysinaliev, Deputy Governor of Jizzakh Province, Uzbekistan, and Azizjon Ibraimov, Deputy Minister of Investment and Trade of Jizzakh Province, visited Shanghai Unicornshell Pharmaceutical Technology Co., Ltd. for an exchange. Unicornshell Chairman Liu Naiyu and his management team warmly received the delegation, accompanied them on a tour, and introduced the company's innovative research and development and industrial layout in the field of plant-based pharmaceutical excipients.
The delegation focused on understanding the process innovations of plant-based hollow capsules, the achievements of traditional Chinese medicine modernization projects, and the expansion of international markets. They also engaged in in-depth discussions on the upgrading needs of the pharmaceutical industry in Central Asia. Both sides explored cooperation pathways to promote the application of plant-based pharmaceutical excipient technologies under the “Belt and Road” framework.
Unicornshell focuses on the research, development, production, and sales of plant-based pharmaceutical excipients. It has launched hydroxypropyl methylcellulose capsules (first generation) and hydroxypropyl starch capsules (second generation), which are widely used in the pharmaceutical and nutritional supplement industries, driving the process of domestic substitution.
During the visit, Deputy Governor Utkirjon Muysinaliev of Jizzakh Province highly commended Unicornshell's R&D capabilities, smart manufacturing standards, and product quality, and reached consensus on international cooperation and market expansion. Chairman Liu Naiyu stated that the company will continue to drive development through innovation, strengthen R&D and smart manufacturing, and promote high-quality development of the plant-based capsule industry to meet global pharmaceutical needs for health and safety.
As an active practitioner of the Belt and Road Initiative, Unicornshell has incorporated the Central Asian market into its global strategic layout. Leveraging its international certification advantages, including FDA, Halal, Kosher, and European BRC certifications, the company is gradually establishing regional influence. Relying on its technical and smart manufacturing capabilities in the field of plant-based pharmaceutical excipients, the company is accelerating the export of advanced processes to Central Asia to help local regions build independent production systems. This exchange has opened new pathways for pharmaceutical industry cooperation between China and Uzbekistan. Both parties will deepen technical and localized production cooperation, jointly provide safe and environmentally friendly pharmaceutical solutions, and collaborate with global partners to drive technological innovation and market expansion, thereby establishing a new international cooperation framework characterized by green, safe, and mutually beneficial outcomes.
